Key result
Pazopanib elicits a clinical response in a patient with metastatic adamantinoma.
Why the study?
Adamantinoma is a rare malignant primary bone tumor with limited data on effective treatments for metastatic cases.
Pazopanib may be an effective treatment option for metastatic adamantinoma.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2013) studied this question. Pazopanib treatment elicited a clinical response in a patient with metastatic adamantinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: